Trial · NCT00679354
Adverse events26
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 26
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic reaction | Immune system disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Constipation | Gastrointestinal disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Depressed level of consciousness | Nervous system disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Facial nerve disorder | Nervous system disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Fatigue | General disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Headache | Nervous system disorders | Treatment (Cilengitide) | 2 | 29 | |
| other | Hypophosphatemia | Metabolism and nutrition disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Lymphocyte count decreased | Investigations | Treatment (Cilengitide) | 2 | 29 | |
| other | Muscle weakness left-sided | Musculoskeletal and connective tissue disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Nervous system disorders - Other, specify | Nervous system disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Neutrophil count decreased | Investigations | Treatment (Cilengitide) | 1 | 29 | |
| other | Peripheral sensory neuropathy | Nervous system disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Skin and subcutaneous tissue disorders - Other, specify | Skin and subcutaneous tissue disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | Upper respiratory infection | Infections and infestations | Treatment (Cilengitide) | 1 | 29 | |
| other | Urinary incontinence | Renal and urinary disorders | Treatment (Cilengitide) | 1 | 29 | |
| other | White blood cell decreased | Investigations | Treatment (Cilengitide) | 1 | 29 | |
| serious | Apnea | Respiratory, thoracic and mediastinal disorders | Treatment (Cilengitide) | 1 | 29 | |
| serious | Buttock pain | Musculoskeletal and connective tissue disorders | Treatment (Cilengitide) | 1 | 29 | |
| serious | Cognitive disturbance | Nervous system disorders | Treatment (Cilengitide) | 1 | 29 | |
| serious | Death NOS | General disorders | Treatment (Cilengitide) | 3 | 29 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00679354/events